ProteinQure, a Toronto, Canada-based biotechnology company developing computational peptide therapeutics, raised $11M in Series A funding.
The round was led by Tom Williams of Heron Rock Fund, with participation from Golden Ventures, Kensington Capital, and others.
The company intends to use the funds to support the initiation of its first clinical trial for PQ203, a first-in-class peptide-drug conjugate for triple-negative breast cancer (TNBC), and the advancement of additional pipeline programs in neurology and nephrology.
Led by CEO Lucas Siow, ProteinQure is a biotechnology company developing ProteinStudio, a proprietary platform that integrates machine learning, structural biology, and atomic-level simulations to design therapeutic peptides using thousands of non-natural amino acids, enabling tissue-specific delivery and access to novel target classes. From cytotoxic payloads to RNA delivery, its precision-designed peptides deliver diverse payloads and generate previously inaccessible targets with broad potential across oncology, neurology, nephrology, and rare disease.
The funding brought the total amount to $16M.
FinSMEs